May 29, 2014
1 min read

BLOG: Ethical dilemmas: insurers offer doctors bonuses for using cheaper medications

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

An article in Tuesday’s Wall Street Journal describes a new payment incentive from WellPoint Health Insurance for oncologists treating breast cancer, in which doctors receive a $350 per month bonus payment for using an insurance-approved chemotherapy regimen.

The approved regimen has been described by leading specialists in the field as reasonable for the majority of patients but is certainly not an ideal fit for everyone.

John Hovanesian

John A. Hovanesian

Furthermore, oncology’s steadily growing array of genetically optimized treatment regimens — with varying degrees of proven success — would persuade at least some results-driven oncologists treating patients away from such conventional regimens.

It has long been illegal for doctors to receive payments from drug companies or other interested parties to prescribe certain brands of medications. 

To read the full blog, click here.